Bone Turnover,Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens

Brown T.T. , Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165–2174.

Dao C. , Young B. , Buchacz K. , Baker R. , Brooks J. , the HIV Outpatient Study Investigators. Higher and increasing rates of fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared to the general US population, 1994 to 2008. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 128.

Triant V.A. , Brown T.T. , Lee H. , Grinspoon S.K. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab 2008; 93: 3499–3504.

Aukrust P. , Haug C.J. , Ueland T. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84: 145–150.

Mondy K. , Yarasheski K. , Powderly W.G. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36: 482–490.

Moore A.L. , Vashisht A. , Sabin C.A. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15: 1731–1733.

Fakruddin J.M. , Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150: 67–78.

Fakruddin J.M. , Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278: 48251–48258.

Ali T. , Lam D. , Bronze M.S. , Humphrey M.B. Osteoporosis in inflammatory bowel disease. Am J Med 2009; 122: 599–604.

Sambrook P. Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther 2007; 9: 107.

van Vonderen M.G. , Lips P. , van Agtmael M.A. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23: 1367–1376.

McComsey G. , Kitch D. , Daar E. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded Phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 106 LB.

Brown T.T. , McComsey G.A. , King M.S. , Qaqish R.B. , Bernstein B.M. , da Silva B.A. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554–561.

Moyle G. , Givens N. , Pearce H. , Compston J. ASSERT. Effect of ART on bone turnover markers and bone density in HIV infected patients. 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV. 26–28 October 2009, Philadelphia, PA, USA. Abstract 019.

Seminari E. , Castagna A. , Soldarini A. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005; 6: 145–150.

Mora S. , Sala N. , Bricalli D. , Zuin G. , Chiumello G. , Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15: 1823–1829.

Brown T.T. , McComsey G.A. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15: 425–429.

Kearns A.E. , Khosla S. , Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155–192.

Eastell R. , Hannon R.A. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 2008; 67: 157–162.

Kushida K. , Takahashi M. , Kawana K. , Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 1995; 80: 2447–2450.

Seibel M.J. , Gartenberg F. , Silverberg S.J. , Ratcliffe A. , Robins S.P. , Bilezikian J.P. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992; 74: 481–486.

Rosen C.J. , Hochberg M.C. , Bonnick S.L. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20: 141–151.

Lee A.J. , Hodges S. , Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000; 37: 432–446.

Garnero P. , Sornay-Rendu E. , Chapuy M.C. , Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: 337–349.

Garnero P. , Shih W.J. , Gineyts E. , Karpf D.B. , Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693–1700.

Mallon P.W. , Miller J. , Cooper D.A. , Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971–979.

Cooper D.A. , Bloch M. , Humphries A. Simplification with fixed-dose tenofovir-emtricitaine or abacavir-lamivudine in adults with suppressed HIV replication (The Steal Study): a randomized, open-label, 96-week, non-inferiority trial. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 576.

Castillo A.B. , Tarantal A.F. , Watnik M.R. , Martin R.B. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res 2002; 20: 1185–1189.

Wanner D.P. , Tyndall A. , Walker U.A. Tenofovir-induced osteomalacia. Clin Exp Rheumatol 2009; 27: 1001–1003.

Perrot S. , Aslangul E. , Szwebel T. , Caillat-Vigneron N. , Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009; 15: 72–74.

Badiou S. , De Boever C.M. , Terrier N. , Baillat V. , Cristol J.P. , Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2006; 52: 335–338.

Fux C. , Opravil M. , Cavssini M. Tenofovir and protease inhibitor use are associated with an increased prevalence of proximal tubule dysfunction in the Swiss Cohort Study. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 743.

Fux C. , Hasse B. , Opravil M. Bone turnover, in particular osteoclast activity in patients with confirmed proximal tubulopathy within the Swiss Cohort Study. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 748.

Daniels E.D. , Pettifor J.M. , Moodley G.P. Serum osteocalcin has limited usefulness as a diagnostic marker for rickets. Eur J Pediatr 2000; 159: 730–733.

Demiaux B. , Arlot M.E. , Chapuy M.C. , Meunier P.J. , Delmas P.D. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 1992; 74: 1146–1151.

Tsilchorozidou T. , Yovos J.G. Hypophosphataemic osteomalacia due to de Toni-Debre-Fanconi syndrome in a 19-year old girl. Hormones (Athens) 2005; 4: 171–176.

Viread^® (tenofovir disoproxil fumarate). Prescribing information 2010. Gilead Sciences, Foster City, CA, USA.

Duvivier C. , Kolta S. , Assoumou L. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23: 817–824.

Wang M.W. , Wei S. , Faccio R. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114: 206–213.

Malizia A.P. , Cotter E. , Chew N. , Powderly W.G. , Doran P.P. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses 2007; 23: 243–250.

Cozzolino M. , Vidal M. , Arcidiacono M.V. , Tebas P. , Yarasheski K.E. , Dusso A.S. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17: 513–520.

Kwan Tat S. , Padrines M. , Theoleyre S. , Heymann D. , Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49–60.

Aukrust P. , Muller F. , Lien E. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999; 179: 74–82.

Rácz J.G. Drug use by the members of youth subcultures in Hungary. Int J Addict 1992; 27: 289–300.

Skoumal M. , Kolarz G. , Haberhauer G. , Woloszczuk W. , Hawa G. , Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005; 26: 63–69.

Vega D. , Maalouf N.M. , Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92: 4514–4521.

Hikita A. , Yana I. , Wakeyama H. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 2006; 281: 36846–36855.

Moir S. , Fauci A.S. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235–245.

Hofbauer L.C. , Dunstan C.R. , Spelsberg T.C. , Riggs B.L. , Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776–781.